Brefeldin A

Brefeldin A for 6 h, the relaxation induced by Bradykinin was completely abolished in the presence of 10mM Indomethacin and 30 μM L-NOARG. Treatment with 20 μg/mL Brefeldin A at concentrations between 1 nM and 1 mM abolished Bradykinin-induced [Ca2+]i reduction. Brefeldin A acts on endothelial cells and has no effect on Bradykinin or Substance P-induced [Ca2+]i enhancement. Brefeldin A did not affect the spontaneous phospholipid-dependent binding of GTPS to myr-rARF1, but completely abolished the catalytic exchange of retinal isotonic extract (RIE), and the semi-inhibitory concentration of 2 μM Brefeldin A was 2 μM. Brefeldin A inhibits multiple membrane transport pathways. Brefeldin A acts on the Golgi membrane or brain cell plasm to inhibit guanine nucleotide exchange activity specific to ADP-ribosylation factor. Complete inhibition of Brefeldin A indicates that the retinal extract contains ARF-specific guanine nucleotide exchange factors. Brefeldin A only partially inhibits ADP-ribosylation factor (ARFs) -released retinal isotonic extract (RIE) catalyzed GTPS, even at concentrations up to 300 μM. Brefeldin A induces the fusion of the Golgi apparatus with ER. Brefeldin A abolished the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treats CHO cells to increase sphingomyelin synthesis by two to three times. In addition to B-CLL cells, Brefeldin A also causes apoptosis in multiple myeloma (U266, NCI-H929), JURKAT, HeLa cells, leukemia (HL60, K562, BJAB), colon (HT-29), and prostate, and adenoid cystic tumor cells. HF4.9 and HF28RA cells were treated with 25 ng/mL Brefeldin A to completely inhibit cell growth, while high doses of Brefeldin A (75 ng/mL) were required to completely inhibit the growth of HF1A3 cells. 50-75 ng/mL Brefeldin A treated HF1A3, HF4.9 and HF28RA cells, inhibited cell proliferation within 24 hours in a dose-dependent manner, and the penetration of 3H-thoracine was almost completely stopped when treated with 50 ng/ml. HF1A3, HF4.9, and HF28RA cells were inhibited by 26%, 76%, 87%, and 75%, 87%, respectively, when treated with 75 ng/mL. In YO-PRO 1/PI assay, Brefeldin A induced cell death in a dose-dependent manner.

Note：Product information may be optimized and upgraded. Please refer to the actual label information for accuracy.

Remark：These protocols are for reference only. Solarbio does not independently validate these methods.

Note：

1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.

2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.

3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.